| Ytd | 260.29% | |
| 1y | 326.83% |
| Open | 22.69 | Prev Close | 22.55 | Low | 21.88 | High | 24.92 | Mkt Cap | 253.72M |
| Vol | 126.20K | Avg Vol | 74.04K | EPS | -3.96 | P/E | N/A | Forward P/E | -6.64 |
| Beta | 1.21 | Short Ratio | 0.83 | Inst. Own | 42.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 15.31 | 200-d Avg | 11.30 | 1yr Est | 3.10 |
Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating a
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the
Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana
HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy r